FINWIRES · TerminalLIVE
FINWIRES

HKG:6990

9 stories mentioning HKG:6990Updated 15d ago

Every FINWIRES story that references HKG:6990, newest first.

Asia

SKB Biopharma's New Indication Application for Breast Cancer Drug Candidate Accepted in China

Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990, SHE:002422) new indication application for TROP2 ADC sacituzumab tirumotecan was accepted for review by China's National Medical Products Administration.The drug has been developed for the first-line treatment of patients with recurrent or metastatic triple-negative breast cancer, according to a Thursday Hong Kong bourse filing.This is the sixth indication application accepted by the regulator for the product. The acceptance was based on positive results from a phase III registrational study.

HKG:6990SHE:002422
Asia

SKB Biopharma Gets China Nod for Advanced Solid Tumors Drug Trial

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990, SHE:002422) obtained approval for an investigational new drug application for the clinical trial of SKB565 from China's National Medical Products Administration.The drug is being developed for the treatment of advanced solid tumors, according to a Monday Hong Kong bourse filing.

HKG:6990SHE:002422
Asia

Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$612.66 From HK$544.42, Keeps at Buy

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) has an average rating of buy and mean price target of HK$577.55, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

HKG:6990
Asia

HBM Holdings's Asthma Drug Candidate Secures China's Approval

HBM Holdings (HKG:2142) investigational new drug application for HBM7575, a long-acting bispecific antibody for asthma treatment, has been approved by China's National Medical Products Administration.HBM7575/SKB575, co-developed with Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990), targets thymic stromal lymphopoietin and an undisclosed target to treat asthma, according to a Wednesday Hong Kong bourse filing.Shares of the company rose over 1% in recent trade.

HKG:2142HKG:6990
Asia

Sichuan Kelun-Biotech Receives Nearly 603 Million Yuan From MediLink

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) said it received a further 602.5 million yuan from MediLink Therapeutics as part of a licensing settlement involving YL201, according to a Friday filing with the Hong Kong bourse.The firm said it had so far received 702.7 million yuan from MediLink Therapeutics.Sichuan Kelun-Biotech previously pursued criminal proceedings against MediLink Therapeutics over allegations the firm misappropriated its trade secrets.Both sides then reached a settlement under an out-licensing deal covering several drugs, including YL201.

HKG:6990
Asia

Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$544.42 From HK$438.30, Keeps at Buy

Sichuan Kelun-Biotech Biopharmaceutical Co (HKG:6990) has an average rating of buy and mean price target of HK$550.70, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

HKG:6990
Asia

Kelun Biotech to Present Study Results of Cancer Drugs at American Oncology Meeting

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) will present the results of its registrational studies on sacituzumab tirumotecan (sac-TMT) and lunbotinib fumarate at the 2026 American Society of Clinical Oncology annual meeting, according to a filing by parent Sichuan Kelun Pharmaceutical (SHE:002422) with the Shenzhen bourse.Its study on its sacituzumab tirumotecan drug versus pembrolizumab for advanced non-small cell lung cancer treatment showed a higher response rate for its sac-TMT against pembrolizumab, the filing said.The company will also present results from its study on lunbotinib, which showed an objective response rate of 87.1% on patients with RET-fusion positive non-small cell lung cancer in patients with prior chemotherapy.

HKG:6990SHE:002422
Asia

Sichuan Kelun-Biotech Wins China IND Nod for Cancer Therapy

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) received approval from China's National Medical Products Administration for the investigational new drug application of SKB118, according to a Wednesday Hong Kong bourse filing.The company said the PD-1/VEGF bispecific antibody is intended for the treatment of advanced solid tumors.The approval clears the company to begin clinical trials for the drug candidate in China, the filing said.

HKG:6990
Asia

SKB Biopharma's Application for New Indication of Tumor Drug Accepted in China

Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990) new indication application for sacituzumab tirumotecan was accepted for review by China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The application is for the drug in combination with pembrolizumab as first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer.

HKG:6990

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:6990 in your portfolio
WheelAI
WheelAI
Analyze HKG:6990 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:6990
HKG:6990 News | FINWIRES